Overview

Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Primary evaluation of the safety, tolerability and feasibility regarding specific postoperative complications of an adjuvant treatment with catumaxomab administered after curative tumor resection subsequent to a neoadjuvant chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Neovii Biotech
Treatments:
Antibodies, Bispecific
Catumaxomab